Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor PK/PD dose-ranging study in pediatric sickle cell disease
2014-001006-18Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ticagrelor in sickle cell disease (SCD) (3 arms), sponsored by AstraZeneca. Primary endpoints: P2Y12 reaction units, Maximum plasma concentration and 1 more. Started Jun 2014; status: completed.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2014-001006-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001006-18.